Cargando…
Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model
During factor VIII prophylaxis for severe hemophilia A, bleeding risk increases with time when factor VIII activity is below 1%. However, maintaining trough activity above 1% does not protect all patients from bleeding. The relationship between factor VIII activity during prophylaxis and bleeding ri...
Autores principales: | Tiede, Andreas, Karim, Faraizah Abdul, Jiménez-Yuste, Victor, Klamroth, Robert, Lejniece, Sandra, Suzuki, Takashi, Groth, Andreas, Santagostino, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252934/ https://www.ncbi.nlm.nih.gov/pubmed/32327501 http://dx.doi.org/10.3324/haematol.2019.241554 |
Ejemplares similares
-
Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2019) -
Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A
por: Di Minno, Giovanni, et al.
Publicado: (2019) -
Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
por: Jiménez‐Yuste, Víctor, et al.
Publicado: (2022) -
Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
por: Jonsson, Fredrik, et al.
Publicado: (2021) -
Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
por: Batt, Katharine, et al.
Publicado: (2019)